Single peptide Vial strength 100 mg
Tirzepatide100 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
Tirzepatide, explained simply
A GIP/GLP-1 receptor agonist with metabolic clinical data tied to specific products and indications.
Research area
Weight and metabolism
How it works
Tirzepatide acts at GIP and GLP-1 receptors involved in blood glucose and appetite regulation.
Why it matters
The profile helps readers separate clinical outcomes from nominal vial contents.
What has been observed
Clinical programs have assessed weight and type 2 diabetes outcomes.
Effects and points to consider
Documented efficacy concerns studied products and indications; it does not automatically validate different preparations.
01 / Vial strength 100 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 100 mg Tirzepatide |
|---|---|
| Final volume | 2.5 mL |
| Concentration | 40 mg/mL |
| One U-100 unit | 400 mcg in 0.01 mL |
Standard Weekly Escalation Schedule (2.5 mL = 40 mg/mL)
| Study Phase | Weekly Amount | U-100 Units | Volume |
|---|---|---|---|
| Weeks 1 to 4 | 2.5 mg | 6.25 units | 0.0625 mL |
| Weeks 5 to 8 | 5 mg | 12.5 units | 0.125 mL |
| Weeks 9 to 12 | 7.5 mg | 18.75 units | 0.1875 mL |
| Weeks 13 to 16 | 10 mg | 25 units | 0.25 mL |
| Weeks 17 to 20 | 12.5 mg | 31.25 units | 0.3125 mL |
| Weeks 21+ | 15 mg | 37.5 units | 0.375 mL |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.